Novozymes and Prometic Life Sciences have entered into a strategic alliance regarding proprietary albumin purification technology.
The technology is based on a synthetic-ligand affinity adsorbent developed by Prometic's UK subsidiary Prometic Biosciences.
The purification technology has been designed for the rapid and cost-effective development of Novozymes's albufuse albumin-fusion molecules.
Under the terms of the co-marketing alliance, the companies will jointly promote the use of a new synthetic-ligand affinity adsorbent - marketed under the trade name Albupure - as a platform approach for the purification of albumin and albumin-fusion proteins.
Prometic will be the exclusive manufacturer and supplier of Albupure, however, both parties will retain ownership of their respective technologies and both Novozymes and Prometic will have the right to market Albupure.
Prometic and Novozymes Biopharma, a subsidiary of Novozymes, have collaborated on the development of Albupure, which was derived from Prometic's Mimetic Ligand technology and targeted at the capture and purification of recombinant albumim proteins produced in yeast.
Albupure binds specifically to the albumin portion of the molecule and so can be used for the purification of any albufuse albumin-fusion protein.
